| Neutrophil extracellular traps and by-products play a key role in COVID-19: pathogenesis, risk factors, and therapy AR Thierry, B Roch Journal of clinical medicine 9 (9), 2942, 2020 | 113 | 2020 |
| Cachexia-sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors B Roch, A Coffy, S Jean-Baptiste, E Palaysi, JP Daures, JL Pujol, ... Lung Cancer 143, 19-26, 2020 | 105 | 2020 |
| Circulating nuclear DNA structural features, origins, and complete size profile revealed by fragmentomics C Sanchez, B Roch, T Mazard, P Blache, ZAA Dache, B Pastor, ... JCI insight 6 (7), 2021 | 57 | 2021 |
| SARS-CoV2 may evade innate immune response, causing uncontrolled neutrophil extracellular traps formation and multi-organ failure AR Thierry, B Roch Clinical Science 134 (12), 1295-1300, 2020 | 46 | 2020 |
| Ultra-sensitive EGFRT790M Detection as an Independent Prognostic Marker for Lung Cancer Patients Harboring EGFRdel19 Mutations and Treated with First … JA Vendrell, J Mazieres, R Senal, I Rouquette, X Quantin, JL Pujol, ... Clinical Cancer Research 25 (14), 4280-4289, 2019 | 38 | 2019 |
| Lung cancer in France JL Pujol, PA Thomas, P Giraud, MG Denis, B Tretarre, B Roch, S Bommart Journal of Thoracic Oncology 16 (1), 21-29, 2021 | 21 | 2021 |
| An individual patient-data meta-analysis of metronomic oral vinorelbine in metastatic non-small cell lung cancer JL Pujol, A Coffy, A Camerini, A Kotsakis, M Mencoboni, M Gusella, ... PLoS One 14 (8), e0220988, 2019 | 19 | 2019 |
| NETs by-products and extracellular DNA may play a key role in COVID-19 pathogenesis: incidence on patient monitoring and therapy A Thierry, B Roch MDPI AG, 2020 | 17 | 2020 |
| Qualitative study of patients’ decision-making when accepting second-line treatment after failure of first-line chemotherapy JL Pujol, B Roch, C Roth, JP Mérel Plos one 13 (5), e0197605, 2018 | 14 | 2018 |
| Monitoring levels of circulating cell‐free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment B Pastor, T André, J Henriques, I Trouilloud, C Tournigand, M Jary, ... Molecular Oncology 15 (9), 2401-2411, 2021 | 13 | 2021 |
| Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to … B Besse, E Felip, RG Campelo, M Cobo, C Mascaux, A Madroszyk, ... Annals of Oncology 34 (10), 920-933, 2023 | 9 | 2023 |
| Development and validation of a simplified prognostic score in SCLC E Negre, A Coffy, A Langlais, JP Daures, A Lavole, E Quoix, O Molinier, ... JTO Clinical and Research Reports 1 (1), 100016, 2020 | 7 | 2020 |
| Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study N Girard, S Galland-Girodet, V Avrillon, B Besse, M Duruisseaux, ... ESMO open 7 (2), 100418, 2022 | 6 | 2022 |
| Small cell lung cancer and immuno-oncologic agents: End of the cisplatin-etoposide era? JL Pujol, B Roch Revue des Maladies Respiratoires 35 (8), 846-851, 2018 | 5 | 2018 |
| Plasma derived cell-free mitochondrial DNA originates mainly from circulating cell-free mitochondria B Roch, E Pisareva, C Sanchez, B Pastor, R Tanos, A Mirandola, ... bioRxiv, 2021.09. 03.458846, 2021 | 4 | 2021 |
| 1899P Autoimmune diseases in centrally reviewed thymic epithelial tumours (TET) JCB Montanez, MÉ Boucher, E Dansin, M Kerjouan, J Mazieres, E Pichon, ... Annals of Oncology 31, S1078, 2020 | 4 | 2020 |
| Prevalence of autoimmune diseases in thymic epithelial tumors (TET) insights from RYTHMIC. JC Benitez, ME Boucher, E Dansin, M Kerjouan, J Mazieres, E Pichon, ... Journal of Clinical Oncology 38 (15_suppl), 9073-9073, 2020 | 4 | 2020 |
| Comparison of the structures and topologies of plasma extracted circulating nuclear and mitochondrial cell-free DNA E Pisareva, B Roch, C Sanchez, B Pastor, A Mirandola, M Diab-Assaf, ... Frontiers in Genetics 14, 1104732, 2023 | 2 | 2023 |
| Synthetic melanin acts as efficient peptide carrier in cancer vaccine strategy S Cuzzubbo, B Roch, G Darrasse-Jèze, B Hosten, M Leclercq, N Vignal, ... International Journal of Molecular Sciences 23 (23), 14975, 2022 | 2 | 2022 |
| 1010P Assessment of early resistance mechanisms to first-line osimertinib in EGFR-mutant NSCLC using spatial transcriptomics GR de Garibay, B Roch, PG Lopez, D Isla, C Aguado, AC Perez, ... Annals of Oncology 33, S1015-S1016, 2022 | 2 | 2022 |
PujolUniversité de Montpellier. centre hospitalier universitaire de Montpellier在 chu-montpellier.fr 的电子邮件经过验证
PujolUniversité de Montpellier. centre hospitalier universitaire de Montpellier在 chu-montpellier.fr 的电子邮件经过验证
alain THIERRYIRCM INSERM在 inserm.fr 的电子邮件经过验证